JP2017523814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523814A5 JP2017523814A5 JP2017527545A JP2017527545A JP2017523814A5 JP 2017523814 A5 JP2017523814 A5 JP 2017523814A5 JP 2017527545 A JP2017527545 A JP 2017527545A JP 2017527545 A JP2017527545 A JP 2017527545A JP 2017523814 A5 JP2017523814 A5 JP 2017523814A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- hvr
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 76
- 235000001014 amino acid Nutrition 0.000 claims 24
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 21
- 238000006467 substitution reaction Methods 0.000 claims 21
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000048432 human TREM2 Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 229940024606 amino acid Drugs 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 4
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 4
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 210000002540 macrophage Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 3
- 102000003839 Human Proteins Human genes 0.000 claims 3
- 108090000144 Human Proteins Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 102000015833 Cystatin Human genes 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 102000004878 Gelsolin Human genes 0.000 claims 2
- 108090001064 Gelsolin Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 102000016943 Muramidase Human genes 0.000 claims 2
- 108010014251 Muramidase Proteins 0.000 claims 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 2
- 108010071690 Prealbumin Proteins 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 2
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims 2
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims 2
- 108700028909 Serum Amyloid A Proteins 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 2
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims 2
- 102000009190 Transthyretin Human genes 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 108700006666 betaIG-H3 Proteins 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- 108050004038 cystatin Proteins 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000045892 human TYROBP Human genes 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 229960000274 lysozyme Drugs 0.000 claims 2
- 235000010335 lysozyme Nutrition 0.000 claims 2
- 239000004325 lysozyme Substances 0.000 claims 2
- -1 median Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000274 microglia Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 102000013498 tau Proteins Human genes 0.000 claims 2
- 108010026424 tau Proteins Proteins 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 108700024394 Exon Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 claims 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 102400001156 Medin Human genes 0.000 claims 1
- 101800003015 Medin Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101100170937 Mus musculus Dnmt1 gene Proteins 0.000 claims 1
- 101100426015 Mus musculus Trem2 gene Proteins 0.000 claims 1
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 1
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 1
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 150000001483 arginine derivatives Chemical class 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical class N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 150000002741 methionine derivatives Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019218512A JP7326135B2 (ja) | 2014-08-08 | 2019-12-03 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2022029743A JP2022081543A (ja) | 2014-08-08 | 2022-02-28 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2024022882A JP7730936B2 (ja) | 2014-08-08 | 2024-02-19 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035336P | 2014-08-08 | 2014-08-08 | |
| US62/035,336 | 2014-08-08 | ||
| US201562135122P | 2015-03-18 | 2015-03-18 | |
| US201562135110P | 2015-03-18 | 2015-03-18 | |
| US62/135,110 | 2015-03-18 | ||
| US62/135,122 | 2015-03-18 | ||
| PCT/US2015/044396 WO2016023019A2 (en) | 2014-08-08 | 2015-08-08 | Anti-trem2 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218512A Division JP7326135B2 (ja) | 2014-08-08 | 2019-12-03 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523814A JP2017523814A (ja) | 2017-08-24 |
| JP2017523814A5 true JP2017523814A5 (enExample) | 2018-09-27 |
| JP6669749B2 JP6669749B2 (ja) | 2020-03-18 |
Family
ID=55264791
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527545A Active JP6669749B2 (ja) | 2014-08-08 | 2015-08-08 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2019218512A Active JP7326135B2 (ja) | 2014-08-08 | 2019-12-03 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2022029743A Withdrawn JP2022081543A (ja) | 2014-08-08 | 2022-02-28 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2024022882A Active JP7730936B2 (ja) | 2014-08-08 | 2024-02-19 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218512A Active JP7326135B2 (ja) | 2014-08-08 | 2019-12-03 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2022029743A Withdrawn JP2022081543A (ja) | 2014-08-08 | 2022-02-28 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2024022882A Active JP7730936B2 (ja) | 2014-08-08 | 2024-02-19 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20170240631A1 (enExample) |
| EP (2) | EP4066859A1 (enExample) |
| JP (4) | JP6669749B2 (enExample) |
| CN (1) | CN107106679B (enExample) |
| AU (2) | AU2015300787A1 (enExample) |
| CA (2) | CA2955086A1 (enExample) |
| EA (1) | EA201790342A1 (enExample) |
| IL (2) | IL279606B (enExample) |
| MX (2) | MX2017001531A (enExample) |
| SG (2) | SG11201700901SA (enExample) |
| WO (1) | WO2016023019A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| KR20240056629A (ko) * | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US10053515B2 (en) | 2016-01-22 | 2018-08-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor XI antibodies |
| EA201892716A1 (ru) | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| JP2019531332A (ja) * | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| CN108727489B (zh) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | 一种单克隆抗体zk2c2及应用 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3625258A1 (en) | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| US11713487B2 (en) | 2017-07-14 | 2023-08-01 | The Regents Of The University Of California | Methods of predicting transplant rejection risk |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| EP3692158A4 (en) * | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| MX2020006213A (es) * | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| JP7418332B2 (ja) * | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN118271444A (zh) * | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| CN111886246B (zh) * | 2017-12-29 | 2024-12-17 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| CN112566934B (zh) * | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| CR20200566A (es) * | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| SG11202100555PA (en) | 2018-07-27 | 2021-02-25 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| SG11202102162RA (en) * | 2018-09-11 | 2021-04-29 | Univ Washington | Anti-trem-2 agonist antibodies |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) * | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CN113302206A (zh) | 2018-11-26 | 2021-08-24 | 戴纳立制药公司 | 治疗脂质代谢失调的方法 |
| CA3122725A1 (en) * | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| CN109646668B (zh) * | 2019-01-04 | 2019-10-18 | 厦门大学 | 一种多肽用于制备防治阿尔茨海默病药物的用途 |
| JP7543290B2 (ja) * | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2020194317A1 (en) * | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| CN110320368A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| WO2021007110A1 (en) * | 2019-07-05 | 2021-01-14 | University Of Florida Research Foundation, Incorporated | Methods for treating ran protein-associated neurological diseases |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| IL293018A (en) | 2019-11-22 | 2022-07-01 | Lilly Co Eli | trem2 antibodies and their uses |
| CN111000978B (zh) * | 2019-11-22 | 2023-03-10 | 中山大学附属第五医院 | Tlt-2在制备治疗结核病药物中的应用 |
| CN115003699A (zh) * | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| WO2021174003A2 (en) * | 2020-02-26 | 2021-09-02 | Washington University | Compositions and methods for reducing resistance to or enhancing immunotherapy |
| WO2021202590A1 (en) * | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| CA3172451A1 (en) * | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
| US20220089726A1 (en) * | 2020-08-05 | 2022-03-24 | Vigil Neuroscience, Inc. | Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists |
| CN112526143B (zh) * | 2020-12-03 | 2021-08-03 | 中山大学附属第五医院 | 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用 |
| CN115109151B (zh) * | 2021-01-31 | 2024-06-11 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体xy6及其应用 |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3239455A1 (en) * | 2021-11-22 | 2023-05-25 | Vigil Neuroscience, Inc. | Anti-trem2 antibody and uses thereof |
| WO2023114499A1 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| EP4455275A4 (en) * | 2021-12-22 | 2026-03-18 | Univ Kagoshima | MACROPHAGE PRODUCTION METHOD, DIFFERENCE-INDUCING AGENT, DIFFERENCE-INDUCING KIT, MACROPHAGE CULTIVATION METHOD, MACROPHAGE PROPAGATION-PROMOTING AGENT, MACROPHAGE PROLIFERATION-PROMOTING KIT, MACROPHAGE PROLIFERATION METHOD, AND MACROPHAGES |
| CA3243690A1 (en) * | 2022-02-04 | 2023-08-10 | Vivasor, Inc. | ANTIGEN-BINDING PROTEINS THAT BIND TO B7-H3 |
| CA3251872A1 (en) * | 2022-02-17 | 2023-08-24 | Anokion Sa | ANTI-ASGR1 POLYPEPTIDES AND METHODS OF USE FOR IMMUNE TOLERANCE |
| CN114395034B (zh) * | 2022-03-24 | 2022-08-05 | 中国科学院微生物研究所 | 一种高效中和新型冠状病毒的人源抗体及其应用 |
| EP4499695A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| JP2025537157A (ja) * | 2022-11-01 | 2025-11-14 | ビジル・ニューロサイエンス・インコーポレイテッド | 抗ｔｒｅｍ２抗体およびその使用 |
| JP2026505005A (ja) | 2023-01-30 | 2026-02-10 | イーエスアーエル バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経変性障害を治療するためのヒト抗ｔｒｅｍ２抗体 |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| EP4726030A1 (en) * | 2023-06-21 | 2026-04-15 | Kagoshima University | Method for producing human macrophage, differentiation-inducing agent, differentiation-inducing kit, method for inducing differentiation of human macrophage, proliferation-promoting agent for human macrophage, kit for promoting proliferation of human macrophage, method for proliferating human macrophage, and human macrophage |
| CN117561278A (zh) * | 2023-07-19 | 2024-02-13 | 成都优洛生物科技有限公司 | 抗trem2人源化抗体、其抗原结合片段及其应用 |
| AU2024320793A1 (en) | 2023-08-09 | 2026-03-12 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| EP4784626A1 (en) | 2023-09-25 | 2026-08-05 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| IL327310A (en) | 2023-09-25 | 2026-05-01 | Kelonia Therapeutics Inc | Cancer treatment vehicles |
| CN119735683B (zh) * | 2023-12-21 | 2025-10-31 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| US12545729B2 (en) | 2024-06-27 | 2026-02-10 | Mabwell Therapeutics, Inc. | Anti-TREM2 agonist antibodies and antigen-binding fragments thereof that can increase levels of soluble TREM2 in serum and brain tissue |
| EP4710934A1 (en) | 2024-09-13 | 2026-03-18 | Albert-Ludwigs-Universität Freiburg | Targeting of microglia in neurodegenerative diseases |
| CN121517514B (zh) * | 2026-01-15 | 2026-04-14 | 华中科技大学同济医学院附属同济医院 | 一种基于ai从头设计的trem1抑制肽及其应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2331386A1 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) * | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US20090081199A1 (en) | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| JP2004073182A (ja) | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
| AU2003242396A1 (en) | 2002-05-24 | 2003-12-12 | Takeda Pharmaceutical Company Limited | Insulin resistance improving agents |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| DE202006007499U1 (de) * | 2006-05-11 | 2007-01-11 | Osaka University | Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen |
| WO2008042261A2 (en) | 2006-09-28 | 2008-04-10 | Elusys Therapeutics, Inc. | Anti-anthrax antibody, formulations thereof, and methods of use |
| US7673853B2 (en) | 2006-10-12 | 2010-03-09 | Cordell Eldred Ebeling | Fencing section with adjustable fencing members |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2186928A1 (en) | 2008-11-14 | 2010-05-19 | Enthone, Inc. | Method for the post-treatment of metal layers |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| US20130015055A1 (en) * | 2011-07-11 | 2013-01-17 | Hariharakeshava Sarpangala Hegde | Dual plasma source systems and methods for reactive plasma deposition |
| WO2014074942A1 (en) * | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| US20170334977A1 (en) | 2014-10-20 | 2017-11-23 | The Brigham And Women's Hospital, Inc. | Targeting Apolipoprotein E (APOE) in Neurologic Disease |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
-
2015
- 2015-08-08 EA EA201790342A patent/EA201790342A1/ru unknown
- 2015-08-08 IL IL279606A patent/IL279606B/en unknown
- 2015-08-08 SG SG11201700901SA patent/SG11201700901SA/en unknown
- 2015-08-08 MX MX2017001531A patent/MX2017001531A/es unknown
- 2015-08-08 JP JP2017527545A patent/JP6669749B2/ja active Active
- 2015-08-08 EP EP21189092.6A patent/EP4066859A1/en active Pending
- 2015-08-08 AU AU2015300787A patent/AU2015300787A1/en not_active Abandoned
- 2015-08-08 WO PCT/US2015/044396 patent/WO2016023019A2/en not_active Ceased
- 2015-08-08 SG SG10201913611QA patent/SG10201913611QA/en unknown
- 2015-08-08 US US15/502,766 patent/US20170240631A1/en not_active Abandoned
- 2015-08-08 CA CA2955086A patent/CA2955086A1/en active Pending
- 2015-08-08 CA CA3090240A patent/CA3090240A1/en active Pending
- 2015-08-08 EP EP15830235.6A patent/EP3177322A4/en not_active Ceased
- 2015-08-08 CN CN201580054105.8A patent/CN107106679B/zh active Active
-
2017
- 2017-01-15 IL IL250115A patent/IL250115B/en unknown
- 2017-02-02 MX MX2023000334A patent/MX2023000334A/es unknown
-
2018
- 2018-09-21 US US16/138,761 patent/US20190010230A1/en not_active Abandoned
-
2019
- 2019-04-11 US US16/382,117 patent/US11084875B2/en active Active
- 2019-12-03 JP JP2019218512A patent/JP7326135B2/ja active Active
-
2021
- 2021-05-05 AU AU2021202840A patent/AU2021202840B2/en active Active
-
2022
- 2022-02-28 JP JP2022029743A patent/JP2022081543A/ja not_active Withdrawn
- 2022-04-21 US US17/726,367 patent/US20230107639A1/en not_active Abandoned
-
2024
- 2024-02-19 JP JP2024022882A patent/JP7730936B2/ja active Active
-
2025
- 2025-09-12 US US19/327,788 patent/US20260209350A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230257466A1 (en) | Anti-cd28 compositions | |
| JP2020533948A5 (enExample) | ||
| JP7328761B2 (ja) | 多価多重特異性ｏｘ４０結合融合タンパク質 | |
| AU2016304794B2 (en) | Constructs having a SIRP-alpha domain or variant thereof | |
| JP2024009818A5 (enExample) | ||
| US20260132202A1 (en) | Bispecific antibodies that bind pd-l1 and cd28 | |
| US12378326B2 (en) | Anti-CD28 x anti-PSMA antibodies | |
| JP7543247B2 (ja) | ヒトＴｉｍ－３に対するモノクローナル抗体 | |
| JP2021530960A5 (enExample) | ||
| JP2018537956A5 (enExample) | ||
| JP2021513329A5 (enExample) | ||
| RU2019108429A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP7128819B2 (ja) | Ａｄａｍ９結合分子、およびその使用方法 | |
| JP2018517401A5 (enExample) | ||
| US20240059786A1 (en) | Anti-cd28 x anti-trop2 antibodies | |
| TW202233674A (zh) | 用於調節δγ鏈介導之免疫的組成物及方法 | |
| JP2022542964A5 (enExample) | ||
| JP2021531027A5 (enExample) | ||
| US20230340128A1 (en) | Anti-cd28 x anti-msln antibodies | |
| US20250084179A1 (en) | Anti-cd28 x anti-trop2 antibodies | |
| US20250206820A1 (en) | Ilt3 and cd3 binding agents and methods of use thereof | |
| CN111448217A (zh) | 双特异性抗原结合构建体 | |
| TW202525853A (zh) | 抗ｃｄ２０ｘ抗ｃｄ２８組合療法 | |
| WO2024216226A1 (en) | Anti-cd28 x anti-enpp3 antibodies | |
| US20230046416A1 (en) | Chemically Induced Association and Dissociation of Therapeutic FC Compositions and Chemically Induced Dimerization of T Cell Engager with Human Serum Albumin |